Cargando…

Randomised trial on clinical performances and biocompatibility of four high-flux hemodialyzers in two mode treatments: hemodialysis vs post dilution hemodiafiltration

This prospective multicenter randomized comparative cross-over trial aimed at evaluating the influence of hemodialysis vs post-dilution hemodiafiltration with high-flux dialyzers in solute clearance and biocompatibility profile. 32 patients were sequentially dialyzed with Leoceed-21HX, Polypure-22S+...

Descripción completa

Detalles Bibliográficos
Autores principales: Morena, Marion, Creput, Caroline, Bouzernidj, Mouloud, Rodriguez, Annie, Chalabi, Lotfi, Seigneuric, Bruno, Lauret, Céline, Bargnoux, Anne-Sophie, Dupuy, Anne-Marie, Cristol, Jean-Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6892817/
https://www.ncbi.nlm.nih.gov/pubmed/31797880
http://dx.doi.org/10.1038/s41598-019-54404-7
_version_ 1783476087040245760
author Morena, Marion
Creput, Caroline
Bouzernidj, Mouloud
Rodriguez, Annie
Chalabi, Lotfi
Seigneuric, Bruno
Lauret, Céline
Bargnoux, Anne-Sophie
Dupuy, Anne-Marie
Cristol, Jean-Paul
author_facet Morena, Marion
Creput, Caroline
Bouzernidj, Mouloud
Rodriguez, Annie
Chalabi, Lotfi
Seigneuric, Bruno
Lauret, Céline
Bargnoux, Anne-Sophie
Dupuy, Anne-Marie
Cristol, Jean-Paul
author_sort Morena, Marion
collection PubMed
description This prospective multicenter randomized comparative cross-over trial aimed at evaluating the influence of hemodialysis vs post-dilution hemodiafiltration with high-flux dialyzers in solute clearance and biocompatibility profile. 32 patients were sequentially dialyzed with Leoceed-21HX, Polypure-22S+, Rexsys-27H and VIE-21A. Primary outcome was β2-microglobulin removal. Secondary outcomes were (i) extraction of other uremic solutes (ii) parameters of inflammation and nutrition and (iii) comparative quantification of perdialytic albumin losses (using total ‘TDC’ vs partial ‘PDC’ collection of dialysate). Significant increases in removal rates of β2-microglobulin (84.7 ± 0.8 vs 71.6 ± 0.8 mg/L), myoglobin (65.9 ± 1.3 vs 38.6 ± 1.3 µg/L), free immunoglobulin light chains Kappa (74.9 ± 0.8 vs 55.6 ± 0.8 mg/L), β-trace protein (54.8 ± 1.3 vs 26.8 ± 1.4 mg/L) and orosomucoid (11.0 ± 1.1 vs 6.0 ± 1.1 g/L) but not myostatin (14.8 ± 1.5 vs 13.0 ± 1.5 ng/mL) were observed in HDF compared to HD when pooling all dialyzers. Rexsys and VIE-A use in both HD and HDF subgroups was associated to a better removal of middle/large-size molecules compared to Leoceed and Polypure, except β2-microglobulin for Rexsys. Inflammatory parameters were unchanged between dialyzers without any interaction with dialysis modality. Mean dialysate albumin loss was comparable between TDC and PDC (1.855 vs 1.826 g/session for TDC and PDC respectively). In addition, a significant difference in albumin loss was observed between dialyzers with the highest value (4.5 g/session) observed using Rexsys. Use of all dialyzers was associated with good removals of the large spectrum of uremic toxins tested and good biocompatibility profiles, with an additional gain in removal performances with HDF. Larger surface area, thinner wall and resultant very high ultrafiltration coefficient of Rexsys should be taken into account in its clear performance advantages.
format Online
Article
Text
id pubmed-6892817
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-68928172019-12-10 Randomised trial on clinical performances and biocompatibility of four high-flux hemodialyzers in two mode treatments: hemodialysis vs post dilution hemodiafiltration Morena, Marion Creput, Caroline Bouzernidj, Mouloud Rodriguez, Annie Chalabi, Lotfi Seigneuric, Bruno Lauret, Céline Bargnoux, Anne-Sophie Dupuy, Anne-Marie Cristol, Jean-Paul Sci Rep Article This prospective multicenter randomized comparative cross-over trial aimed at evaluating the influence of hemodialysis vs post-dilution hemodiafiltration with high-flux dialyzers in solute clearance and biocompatibility profile. 32 patients were sequentially dialyzed with Leoceed-21HX, Polypure-22S+, Rexsys-27H and VIE-21A. Primary outcome was β2-microglobulin removal. Secondary outcomes were (i) extraction of other uremic solutes (ii) parameters of inflammation and nutrition and (iii) comparative quantification of perdialytic albumin losses (using total ‘TDC’ vs partial ‘PDC’ collection of dialysate). Significant increases in removal rates of β2-microglobulin (84.7 ± 0.8 vs 71.6 ± 0.8 mg/L), myoglobin (65.9 ± 1.3 vs 38.6 ± 1.3 µg/L), free immunoglobulin light chains Kappa (74.9 ± 0.8 vs 55.6 ± 0.8 mg/L), β-trace protein (54.8 ± 1.3 vs 26.8 ± 1.4 mg/L) and orosomucoid (11.0 ± 1.1 vs 6.0 ± 1.1 g/L) but not myostatin (14.8 ± 1.5 vs 13.0 ± 1.5 ng/mL) were observed in HDF compared to HD when pooling all dialyzers. Rexsys and VIE-A use in both HD and HDF subgroups was associated to a better removal of middle/large-size molecules compared to Leoceed and Polypure, except β2-microglobulin for Rexsys. Inflammatory parameters were unchanged between dialyzers without any interaction with dialysis modality. Mean dialysate albumin loss was comparable between TDC and PDC (1.855 vs 1.826 g/session for TDC and PDC respectively). In addition, a significant difference in albumin loss was observed between dialyzers with the highest value (4.5 g/session) observed using Rexsys. Use of all dialyzers was associated with good removals of the large spectrum of uremic toxins tested and good biocompatibility profiles, with an additional gain in removal performances with HDF. Larger surface area, thinner wall and resultant very high ultrafiltration coefficient of Rexsys should be taken into account in its clear performance advantages. Nature Publishing Group UK 2019-12-04 /pmc/articles/PMC6892817/ /pubmed/31797880 http://dx.doi.org/10.1038/s41598-019-54404-7 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Morena, Marion
Creput, Caroline
Bouzernidj, Mouloud
Rodriguez, Annie
Chalabi, Lotfi
Seigneuric, Bruno
Lauret, Céline
Bargnoux, Anne-Sophie
Dupuy, Anne-Marie
Cristol, Jean-Paul
Randomised trial on clinical performances and biocompatibility of four high-flux hemodialyzers in two mode treatments: hemodialysis vs post dilution hemodiafiltration
title Randomised trial on clinical performances and biocompatibility of four high-flux hemodialyzers in two mode treatments: hemodialysis vs post dilution hemodiafiltration
title_full Randomised trial on clinical performances and biocompatibility of four high-flux hemodialyzers in two mode treatments: hemodialysis vs post dilution hemodiafiltration
title_fullStr Randomised trial on clinical performances and biocompatibility of four high-flux hemodialyzers in two mode treatments: hemodialysis vs post dilution hemodiafiltration
title_full_unstemmed Randomised trial on clinical performances and biocompatibility of four high-flux hemodialyzers in two mode treatments: hemodialysis vs post dilution hemodiafiltration
title_short Randomised trial on clinical performances and biocompatibility of four high-flux hemodialyzers in two mode treatments: hemodialysis vs post dilution hemodiafiltration
title_sort randomised trial on clinical performances and biocompatibility of four high-flux hemodialyzers in two mode treatments: hemodialysis vs post dilution hemodiafiltration
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6892817/
https://www.ncbi.nlm.nih.gov/pubmed/31797880
http://dx.doi.org/10.1038/s41598-019-54404-7
work_keys_str_mv AT morenamarion randomisedtrialonclinicalperformancesandbiocompatibilityoffourhighfluxhemodialyzersintwomodetreatmentshemodialysisvspostdilutionhemodiafiltration
AT creputcaroline randomisedtrialonclinicalperformancesandbiocompatibilityoffourhighfluxhemodialyzersintwomodetreatmentshemodialysisvspostdilutionhemodiafiltration
AT bouzernidjmouloud randomisedtrialonclinicalperformancesandbiocompatibilityoffourhighfluxhemodialyzersintwomodetreatmentshemodialysisvspostdilutionhemodiafiltration
AT rodriguezannie randomisedtrialonclinicalperformancesandbiocompatibilityoffourhighfluxhemodialyzersintwomodetreatmentshemodialysisvspostdilutionhemodiafiltration
AT chalabilotfi randomisedtrialonclinicalperformancesandbiocompatibilityoffourhighfluxhemodialyzersintwomodetreatmentshemodialysisvspostdilutionhemodiafiltration
AT seigneuricbruno randomisedtrialonclinicalperformancesandbiocompatibilityoffourhighfluxhemodialyzersintwomodetreatmentshemodialysisvspostdilutionhemodiafiltration
AT lauretceline randomisedtrialonclinicalperformancesandbiocompatibilityoffourhighfluxhemodialyzersintwomodetreatmentshemodialysisvspostdilutionhemodiafiltration
AT bargnouxannesophie randomisedtrialonclinicalperformancesandbiocompatibilityoffourhighfluxhemodialyzersintwomodetreatmentshemodialysisvspostdilutionhemodiafiltration
AT dupuyannemarie randomisedtrialonclinicalperformancesandbiocompatibilityoffourhighfluxhemodialyzersintwomodetreatmentshemodialysisvspostdilutionhemodiafiltration
AT cristoljeanpaul randomisedtrialonclinicalperformancesandbiocompatibilityoffourhighfluxhemodialyzersintwomodetreatmentshemodialysisvspostdilutionhemodiafiltration